血红素加氧酶-1在慢性肝病发病中的作用研究进展*

doi:10.3969/j.issn.1672-5069.2015.02.031

Abstract

Ji Xiaoqin, Li Lei. Heme oxygenase-1 in the pathogenesis of chronic liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 321-324.

[1] Gozzelino R,Jeney V,Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol,2010,50:323-354.
[2] Paine A,Eiz-Vesper B,Blasczyk R,et al. Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem Pharmacol,2010,80（12）:1895-1903.
[3] Vijayan V,Mueller S,Baumgart-Vogt E,et al. Heme oxygenase-1 as a therapeutic target in inflammatory disorders of the gastrointestinal tract. World J Gastroenterol,2010,16（25）:3112-3119.
[4] Farombi EO,Surh YJ. Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J Biochem Mol Biol,2006,39（5）:479-491.
[5] Suliburk JW,Ward JL,Helmer KS,et al. Ketamine-induced hepatoprotection:the role of heme oxygenase-1. Am J Physiol Gastrointest Liver Physiol,2009,296（6）:G1360-1369.
[6] Gozzelino R,Jeney V,Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol,2010,50:323-354.
[7] Soares MP,Marguti I,Cunha A,et al. Immunoregulatory effects of HO-1:how does it work Curr Opin Pharmacol,2009,9（4）:482-489.
[8] Biburger M,Theiner G,Schadle M,et al. Pivotal advance: Heme oxygenase 1 expression by human CD4 + T cells is not sufficient for their development of immunoregulatory capacity. J Leukoc Biol,2010,87（2）:193-202.
[9] Farombi EO,Surh YJ. Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J Biochem Mol Biol,2006,39（5）:479-491.
[10] Abdalla MY,Britigan BE,Wen F,et al Down-regulation of heme oxygenase-1 by hepatitis C virus infection in vivo and by the in vitro expression of hepatitis C core protein. J Infect Dis,2004,190（6）:1109-1118.
[11] Protzer U,Seyfried S,Quasdorff M,et al. Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. Gastroenterology,2007,133（4）:1156-1165.
[12] 李磊,韩华,金坤,等. 血红素加氧酶-1表达对HBV复制的反向调控作用. 肝脏,2013,18（10）:592-596.
[13] Lin L,Hu J. Inhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by porphyrin compounds. J Virol,2008,82（5）:2305-2312.
[14] Zhu Z,Wilson AT,Mathahs MM,et al. Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology,2008,48（5）:1430-1439.
[15] Fillebeen C,Rivas-Estilla AM, Bisaillon M,et al. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J Biol Chem,2005,280（10）:9049-9057.
[16] Yuasa K,Naganuma A,Sato K,et al. Zinc is a negative regulator of hepatitis C virus RNA replication. Liver Int,2006,26（9）:1111-1118.
[17] Zhu Z,Wilson AT,Luxon BA,et al. Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity:mechanism for the antiviral effects of heme oxygenase Hepatology,2010,52（6）:1897-1905.
[18] Hou W,Tian Q,Zheng J,et al. Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells. Gastroenterology,2010,138（5）:1909-1919.
[19] Lehmann E,El-Tantawy WH,Ocker M,et al. The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology,2010,51（2）:398-404.
[20] Kalliolias GD,Ivashkiv LB. Overview of the biology of type I interferons. Arthritis Res Ther,2010,12 （Suppl 1）:S1.
[21] Lehmann E,El-Tantawy WH,Ocker M,et al. The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology,2010,51（2）:398-404.
[22] Lundvig DM,Immenschuh S,Wagener FA. Heme oxygenase, inflammation,and fibrosis: the good,the bad,and the ugly Front Pharmacol,2012,3:81.
[23] Bessa SS,Mohamed Ali EM,Abd El-Wahab Ael-S,et al. Heme oxygenase-1 mRNA expression in egyptian patients with chronic liver disease. Hepat Mon,2012,12（4）:278-285.
[24] Guo SB, Li Q, Duan ZJ, et al. Octreotide attenuates liver fibrosis by inhibiting hepatic heme oxygenase-1 expression. Mol Med Rep,2015,11（1）:83-90.
[25] Wang QM,Du JL,Duan ZJ,et al. Inhibiting heme oxygenase-1 attenuates rat liver fibrosis by removing iron accumulation. World J Gastroenterol,2013,19（19）:2921-2934.
[26] Wang F,Duan ZJ,Sun YJ. Influence of heme oxygenase-1 expression on immune liver fibrosis induced by cobalt protoporphyrin in rats. World J Gastroenterol,2009,15（24）:3009-3014.
[27] Yang H,Zhao LF,Zhao ZF,et al. Heme oxygenase-1 prevents liver fibrosis in rats by regulating the expression of PPARγ and NF-κB. World J Gastroenterol,2012,18（14）:1680-1688.
[28] Barikbin R,Neureiter D,Wirth J,et al. Induction of heme oxygenase 1 prevents progression of liver fibrosis in Mdr2 knockout mice. Hepatology,2012,55（2）:553-562.
[29] Zou C,Zhang H,Li Q,et al. Heme oxygenase-1:a molecular brake on hepatocellular carcinoma cell migration. Carcinogenesis, 2011,32（12）:1840-1848.
[30] Sass G,Leukel P,Schmitz V,et al. Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. Int J Cancer,2008,123（6）:1269-1277.
[31] Sun L,Shi T,Qiao H,et al. Hepatic overexpression of heme oxygenase-1 improves liver allograft survival by expanding T regulatory cells. J Surg Res,2011,166（2）:e187-194.
[32] Ben-Ari Z1,Issan Y,Katz Y,et al. Induction of heme oxygenase-1 protects mouse liver from apoptotic ischemia/reperfusion injury. Apoptosis,2013,18（5）:547-555.
[33] Wang CF,Wang ZY,Tao SF,et al. Preconditioning donor liver with Nodosin perfusion lessens rat ischemia reperfusion injury via heme oxygenase-1 upregulation. J Gastroenterol Hepatol,2012,27（4）:832-840.
[34] Matsumi J,Morimatsu H,Matsusaki T,et al. Heme breakdown and ischemia/reperfusion injury in grafted liver during living donor liver transplantation. Int J Mol Med,2012,29（2）:135-140.
[35] Tamura T,Kondo T,Ogawa K,et al. Protective effect of heme oxygenase-1 on hepatic ischemia-reperfusion injury through inhibition of platelet adhesion to the sinusoids. J Gastroenterol Hepatol,2013,28（4）:700-706.
[36] Kim SJ,Eum HA,Billiar TR,et al. Role of heme oxygenase 1 in TNF/TNF receptor-mediated apoptosis after hepatic ischemia/reperfusion in rats. Shock,2013,39（4）:380-388.
[37] Yun N,Cho HI,Lee SM. Impaired autophagy contributes to hepatocellular damage during ischemia/reperfusion:heme oxygenase-1 as a possible regulator. Free Radic Biol Med,2014,68:168-177.
[38] Wang Y,Shen J,Xiong X,et al. Remote ischemic preconditioning protects against liver ischemia-reperfusion injury via heme oxygenase-1-induced autophagy. PLoS One,2014,9（6）:e98834.

Heme oxygenase-1 in the pathogenesis of chronic liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[2]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[3]	Lin Qiuxiang, Wang Xuewen, Huang Zuxiong, et al. Protective effects of breviscapine on liver and intestinal mucosal barrier functions in rats with hepatic ischemia-reperfusion injury [J]. Journal of Practical Hepatology, 2019, 22(5): 636-639.
[4]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[5]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[6]	Liu Xing, Zhao Shuli, Zhang Dianlong. Effect of sevoflurane inhalation on hepatic ischemia-reperfusion injury in patients with primary liver cancer undergoing partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(5): 728-731.
[7]	Wang Yan, Su Feng, Li Yuanyuan, et al. Protective effect of bee venom hemolysin on rats with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 474-477.
[8]	Qiao Zhizhong. Value of contrast-enhanced ultrasonography in differential diagnosis of patients with focal nodular hyperplasia and hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 421-424.
[9]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[10]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[11]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[12]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.
[13]	Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.
[14]	Wang Zhaoxia, Guan Ke, Fu Sanxian, Wang Huijie. Early administration of enteral nutrition in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 272-275.
[15]	Zhao Xitai, Nie Qinghe. Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 297-300.